Evolution of Aspergillus fumigatus virulence
Evolution of Aspergillus fumigatus virulence
批准号:
10753216
负责人:
Robert Andrew Cramer
金额:
$57.23万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
未结题
起止时间:
2017-09-25 至 2028-06-30
关键词:
AcuteAddressAdrenal Cortex HormonesAllergic Bronchopulmonary AspergillosisAnimal ModelAntifungal AgentsAntifungal TherapyArchitectureAspergillosisAspergillusAspergillus fumigatusBiomassCarbonCell CommunicationCellsChronicClinicalCommunitiesDataDevelopmentDiseaseDisease OutcomeDisease ProgressionDoseDrug resistanceEnvironmentEthanolEvolutionExhibitsFoundationsFundingGene ClusterGene FamilyGenesGeneticGenomicsGlucoseGoalsGossypiumGrowthHealthHeterogeneityHourHumanHypoxiaImmuneImmune systemImmunityInfectionKnowledgeLaboratoriesLeukocytesMediatingMetabolicMetabolismMicrobial BiofilmsModelingMolecularMorphologyMycosesNeutrophil InfiltrationOxygenPathway interactionsPatient IsolationPatientsPatternPhenotypePhysiologicalPhysiologyPilot ProjectsPopulationPredispositionPropertyProtein AnalysisProteinsResearchRoleSiteSourceStudy modelsSuppressor MutationsTertiary Protein StructureTestingTherapeuticVirulenceVirulentWorkchemotherapycombatderepressionfitnessgene functiongenetic analysishuman diseaseimmunoregulationin vivoinnovationinsightlung injurymouse modelneutrophilnovelnovel diagnosticsnovel therapeutic interventionpathogenic funguspatient populationresistant strainsuccesstool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary. Fungal mediated disease progression is highlighted by populations of fungal cells that form
a community referred to as a biofilm. For therapeutic success, contemporary antifungal therapies must be
effective at the site of infection in the context of an established fungal biofilm. Critically, it is now clear that
emergent properties arise from fungal biofilms that directly alter virulence, disease progression, and antifungal
drug susceptibility. However, the mechanisms through which filamentous fungal biofilm emergent properties
impact virulence, disease progression, and antifungal susceptibility remain a significant knowledge gap. The
long-term goal of this project is focused on defining the molecular mechanisms of Aspergillus fumigatus biofilm
mediated disease progression mechanisms to inform contemporary and novel therapeutic approaches. In the
prior funding period, we made important progress that surprisingly revealed heterogeneity in A. fumigatus
biofilm morphology across clinical isolates. Differences in biofilm morphology altered virulence and disease
progression in vivo in murine models of aspergillosis. We discovered that long term growth in a low oxygen
environment gives rise to a biofilm morphology we termed H-MORPH and that a novel fungal specific gene
cluster that contains a protein with unknown function was sufficient for H-MOPRH formation. Significantly, we
identified H-MORPH clinical isolates from both acute invasive aspergillosis patients and patients with chronic
aspergillosis, suggesting H-MORPH can arise in human disease. We observed that H-MOPRH occurs in vivo
in a murine model of invasive pulmonary aspergillosis and contributes to worse disease outcomes compared to
the contrasting N-MORPH isolates. In aim 1, we will define the genetic pathway(s) that regulate A. fumigatus
the development of this unique population level morphotype utilizing the newly discovered biofilm architecture
factor (baf) gene family as a tool to dissect the underlying mechanisms. In aim 2, we will define the differences
in fungal metabolism that underly N-MORPH and H-MORPH morphotypes and test the hypothesis that H-
MORPH biofilms are carbon catabolite de-repressed which leads to increased fitness in vivo. In aim 3, we test
the hypothesis that H-MORPH strain metabolism is immune modulatory through alterations in fungal pathogen
associated molecular pattern exposure. Taken together, our proposed studies will fill significant knowledge
gaps related to the discovery of distinct A. fumigatus morphotypes that directly impact virulence. Advancing our
understanding of this knowledge gap is expected to lay the foundation for new diagnostic and therapeutic
strategies to combat highly virulent and drug resistant strains of this important human fungal pathogen.
期刊论文(8)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1128/mbio.03483-20
发表时间:
2021-02-09
期刊:
mBio
影响因子:
6.4
作者:
[Cramer RA, Kowalski CH]
通讯作者:
Kowalski CH
DOI:
10.1128/mbio.02425-22
发表时间:
2022-12-20
期刊:
mBio
影响因子:
6.4
作者:
[]
通讯作者:
DOI:
10.1080/22221751.2020.1847001
发表时间:
2020-12
期刊:
Emerging microbes & infections
影响因子:
13.2
作者:
[Eudes Filho J, Santos IBD, Reis CMS, Patané JSL, Paredes V, Bernardes JPRA, Poggiani SDSC, Castro TCB, Gomez OM, Pereira SA, Schubach EYP, Gomes KP, Mavengere H, Alves LGB, Lucas J, Paes HC, Albuquerque P, Cruz LM, McEwen JG, Stajich JE, Almeida-Paes R, Zancopé-Oliveira RM, Matute DR, Barker BM, Felipe MSS, Teixeira MM, Nicola AM]
通讯作者:
Nicola AM
Environmental Oxygen Transitions and Aspergillosis Disease Progression
-
批准号:10615129
-
项目类别:
-
资助金额:$52.94万
-
财政年份:2019
-
负责人:Robert Andrew Cramer
-
依托单位:
Antifungal Immunity and the Mechanism of Fungal Programmed Cell Death
-
批准号:10538624
-
项目类别:
-
资助金额:$65.3万
-
财政年份:2019
-
负责人:Robert Andrew Cramer
-
依托单位:
Environmental Oxygen Transitions and Aspergillosis Disease Progression
-
批准号:10404535
-
项目类别:
-
资助金额:$52.94万
-
财政年份:2019
-
负责人:Robert Andrew Cramer
-
依托单位:
Antifungal Immunity and the Mechanism of Fungal Programmed Cell Death
-
批准号:10320401
-
项目类别:
-
资助金额:$65.3万
-
财政年份:2019
-
负责人:Robert Andrew Cramer
-
依托单位:
Overcoming Emerging Aspergillus fumigatus Azole Resistance Via Protease Inhibition
-
批准号:10547781
-
项目类别:
-
资助金额:$44.62万
-
财政年份:2019
-
负责人:Robert Andrew Cramer
-
依托单位:
Antifungal Immunity and the Mechanism of Fungal Programmed Cell Death
-
批准号:10079460
-
项目类别:
-
资助金额:$65.3万
-
财政年份:2019
-
负责人:Robert Andrew Cramer
-
依托单位:
Environmental Oxygen Transitions and Aspergillosis Disease Progression
-
批准号:10161719
-
项目类别:
-
资助金额:$52.94万
-
财政年份:2019
-
负责人:Robert Andrew Cramer
-
依托单位:
Overcoming Emerging Aspergillus fumigatus Azole Resistance Via Protease Inhibition
-
批准号:10334562
-
项目类别:
-
资助金额:$44.19万
-
财政年份:2019
-
负责人:Robert Andrew Cramer
-
依托单位:
Overcoming Emerging Aspergillus fumigatus Azole Resistance Via Protease Inhibition
-
批准号:10320260
-
项目类别:
-
资助金额:$44.46万
-
财政年份:2019
-
负责人:Robert Andrew Cramer
-
依托单位:
Evolution of Aspergillus fumigatus virulence
-
批准号:10238878
-
项目类别:
-
资助金额:$45.49万
-
财政年份:2017
-
负责人:Robert Andrew Cramer
-
依托单位:
Evolution of Aspergillus fumigatus virulence
-
批准号:9764247
-
项目类别:
-
资助金额:$45.49万
-
财政年份:2017
-
负责人:Robert Andrew Cramer
-
依托单位:
MECHANISMS OF ALCOHOL PATHOGENESIS IN RESPONSE TO HYPOXIA IN A FUMIGATUS
-
批准号:8360162
-
项目类别:
-
资助金额:$20.94万
-
财政年份:2011
-
负责人:Robert Andrew Cramer
-
依托单位:
MECHANISMS OF ALCOHOL PATHOGENESIS IN RESPONSE TO HYPOXIA IN A FUMIGATUS
-
批准号:8168416
-
项目类别:
-
资助金额:$20.73万
-
财政年份:2010
-
负责人:Robert Andrew Cramer
-
依托单位:
Hypoxia Adaptation and Fungal Virulence of Aspergillus fumigatus
-
批准号:9093682
-
项目类别:
-
资助金额:$40.5万
-
财政年份:2009
-
负责人:Robert Andrew Cramer
-
依托单位:
Hypoxia Adaptation and Fungal Virulence of Aspergillus fumigatus
-
批准号:8759323
-
项目类别:
-
资助金额:$40.5万
-
财政年份:2009
-
负责人:Robert Andrew Cramer
-
依托单位:
Hypoxia Adaptation and Fungal Virulence of Aspergillus fumigatus
-
批准号:8901906
-
项目类别:
-
资助金额:$40.5万
-
财政年份:2009
-
负责人:Robert Andrew Cramer
-
依托单位:
ALCOHOL FERMENTATION AND PATHOGENESIS IN RESPONSE TO HYPOXIA IN A FUMIGATUS
-
批准号:7960529
-
项目类别:
-
资助金额:$13.41万
-
财政年份:2009
-
负责人:Robert Andrew Cramer
-
依托单位:
Hypoxia Adapatation and Fungal Virulence of Aspergillus fumigatus
-
批准号:7910533
-
项目类别:
-
资助金额:$31.32万
-
财政年份:2009
-
负责人:Robert Andrew Cramer
-
依托单位:
Hypoxia Adapatation and Fungal Virulence of Aspergillus fumigatus
-
批准号:8131728
-
项目类别:
-
资助金额:$31.01万
-
财政年份:2009
-
负责人:Robert Andrew Cramer
-
依托单位:
Hypoxia Adapatation and Fungal Virulence of Aspergillus fumigatus
-
批准号:7633024
-
项目类别:
-
资助金额:$31.64万
-
财政年份:2009
-
负责人:Robert Andrew Cramer
-
依托单位:
海外基金